Seeking Alpha

More on Raptor Pharmaceutical (RPTP): Q4 EPS misses estimates by a large margin, and are down...

More on Raptor Pharmaceutical (RPTP): Q4 EPS misses estimates by a large margin, and are down 28% from the same quarter last year. R&D expenses increased nearly 50% to $9M, driven largely by higher product manufacturing costs for RP103, its treatment for cystinosis, Huntington's disease and non-alcoholic steatohepatitis, plus other supporting study expenses and employee compensation. SG&A costs also ramped up during the quarter due to marketing expenses attributed to RP103 as well.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector